First Lab-in-a-Briefcase to Boost Global Early Diagnosis of Cancer
|
By LabMedica International staff writers Posted on 18 Nov 2015 |

Image: The 4 main components of the newly developed “lab-in-a-briefcase.” (1) Disposable multiple syringe aspirator (MSA) devices, each of which can perform 10 replicate ELISA tests on each of the 8 samples. (2) Customized microwell plates preloaded with reagents that interface with the MSA. (3) Portable USB-powered film scanner for colorimetric signal quantification. (4) Portable computer for real-time data analysis (Photo courtesy of Barbosa AI et al., 2015, and the journal Lab on a Chip.)
To help boost early cancer detection rates worldwide, scientists have developed an all-in-one portable mini-laboratory for point-of-care cancer screening, rapid detection, and monitoring. The prototype successfully tested for prostate cancer, and can operate at even at high temperatures often found in remote areas without air-conditioned clinics.
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
Latest Technology News
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Channels
Clinical Chemistry
view channel
Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more
Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, yet routine screening remains uncommon despite guideline recommendations, leaving many high-risk... Read more
Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disorder marked by amyloid-beta and tau pathology and remains a leading cause of cognitive decline in older adults. Although lecanemab, an anti-amyloid... Read moreMolecular Diagnostics
view channel
Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
Early detection of stage I solid cancers remains a significant unmet clinical need. Liquid biopsy approaches that can distinguish tumor-derived signals from background cell-free DNA are therefore drawing... Read more
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read moreHematology
view channel
New Automated Hemostasis Systems Become Available Across US Laboratories
Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read more
Variation in AML Residual Disease Testing Prompts Push for Standardization
Acute myeloid leukemia (AML) is an aggressive blood cancer in which relapse after therapy remains a persistent challenge, making measurable residual disease (MRD) detection central to risk assessment and... Read moreImmunology
view channel
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channelMagnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more
Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more
CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read moreIndustry
view channel
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Unilabs Expands Digital Pathology Across European Network with Proscia Platform
As precision medicine expands, digital pathology platforms must connect teams, sites, diagnostic data, and artificial intelligence to accelerate routine diagnosis. Sharing expertise across laboratory networks... Read more
MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more







